Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489000 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
J Obstet Gynaecol Can
November 2020
Department of Obstetrics and Gynecology, McGill University, Montréal, QC. Electronic address:
Background: Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts. The patient refused oral contraception and reported that traditional analgesia did not significantly alleviate symptoms. We theorized that the underlying von Willebrand disease compounded the degree of hemorrhage into her recurrent cysts.
View Article and Find Full Text PDFPurpose: To determine if severe periovulatory diarrhea in a woman with Crohn's disease for just one day may be related to increased permeability of the large bowel related to hormonal changes that occur at this time of menstrual cycle.
Materials And Methods: Dextroamphetamine sulfate was given to a woman whose Crohn's disease was markedly improved by adalimumab but who still had one day of severe diarrhea at mid-cycle.
Results: She did not have any diarrhea or frequent defecation for the first two periovulatory times before she achieved pregnancy.
Mittelschmerz mimicking appendicitis.
Br J Hosp Med (Lond)
July 2009
Department of Surgery, University Hospital Lewisham, London, JA
Health benefits of oral contraceptives.
Obstet Gynecol Clin North Am
December 2000
Department of Obstetrics and Gynecology, Oregon Health Sciences University, Portland, USA.
A sizeable literature corroborates the multiple health benefits of oral contraceptive use. The first estrogen/progestin combination pills were marketed to treat a variety of menstrual disorders. Although currently used oral contraceptives no longer carry FDA-approved labeling for these indications, they remain important therapeutic options for a variety of gynecologic conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!